You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠集團(000513.SZ):重組抗人IL-17A/F人源化單克隆抗體已完成Ⅲ期臨牀入組,預計2025年內報產
格隆匯 04-16 15:05

格隆匯4月16日丨麗珠集團(000513.SZ)於近期投資者關係活動表示,麗珠生物作爲公司創新驅動發展的重要佈局,其階段性投入是長期戰略所需。目前麗珠生物重點在研產品中,重組人促卵泡激素注射液已於2025年初申報上市;重組抗人IL-17A/F人源化單克隆抗體已完成Ⅲ期臨牀入組,預計2025年內報產,有望成爲國產首個IL-17雙靶點藥物。未來公司通過資源高效協同與財務風險管控機制,動態優化資源配置,確保研發轉化效率與整體業績穩健性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account